Biotech entity
Every one of those 1 sits in a single category, pharma. Bristol Myers Squibb is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 3 original sources on average, compared with 2.4 for the broader beat in this window.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Bristol Myers Squibb is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 3 original sources on average, compared with 2.4 for the broader beat in this window. The average consequence score is 6, matching the 6 beat baseline for this window. OneSpaWorld appears in 1 tracked Biotech story from February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering OneSpaWorld. Shared-story counts are live from our verified record — not editorial picks.
Halozyme Therapeutics reported a strong revenue beat of $451 million for the fourth quarter, driven by its ENHANZE platform royalties, yet surprised investors with a significant non-GAAP EPS miss of $2.44. The discrepancy suggests substantial one-time charges or strategic shifts that contrast with the company's robust top-line growth.
Source: Seeking Alpha · Seeking Alpha
OneSpaWorld is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
